Table 2.

Univariable analysis of association between time to first AKI by patient characteristics and ICI regimens

Parameter	Category	AKI Definition 1a				AKI Definition 1b
		Hazard Ratio	95% CI	P-Value for Comparison with Reference	P-Value for Overall Effect	Hazard Ratio	95% CI	P-Value for Comparison with Reference	P-Value for Overall Effect
Drug (ref = ’ pembrolizumab’)	Ipilimumab	3.402	1.260–9.186	0.0157	0.0002	4.932	1.695– 14.346	0.0034	<0.0001
	Ipilimumab/nivolumab	4.713	1.542–14.404	0.0065		7.384	2.328– 23.417	0.0007
	Ipilimumab/pembrolizumab	6.281	2.413–16.349	0.0002		9.559	3.370– 27.112	<.0001
	Nivolumab	1.136	0.306–4.222	0.8491		3.242	1.002– 10.490	0.0496
Age_Years	Per year increase	0.980	0.964–0.997	0.0191	0.0191	0.975	0.960– 0.990	0.0009	0.00009
Age (ref = ’Age≤60)	Age>60 years	0.610	0.364–1.021	0.0601	0.061	0.549	0.346– 0.873	0.0112	0.0112
Gender (ref = ’Male’)	Female	0.775	0.440–1.365	0.3775	0.7787	0.989	0.610– 1.604	0.9651	0.9651
Race(ref = ’White’)	Asian	4.995	1.282–19.463	0.0205	0.0205	5.970	2.164– 16.470	0.0006	0.0006
Hypertension	Yes vs No	0.536	0.264–1.089	0.0847	0.0847	0.711	0.397– 1.276	0.2533	0.2533
Liver Disease	Yes vs No	3.096	0.445–21.555	0.2538	0.2538	2.503	0.355– 17.620	0.3570	0.3570
NSAID use	Yes vs No	1.677	0.719–3.913	0.2313	0.2313	2.730	1.436– 5.194	0.0022	0.0022
PPI use	Yes vs No	2.211	1.249–3.915	0.0065	0.0065	2.359	1.424– 3.905	0.0009	0.0009
Baseline eGFR	<60 ml/min/1.73 m2 vs ≥60 ml/min/1.73 m2	0.727	0.332–1.595	0.4268	0.4268	0.567	0.261–1.230	0.1509	0.1509